<div id="report-related">

<h3 style="font-size:12pt">OIG Work Areas</h3>



<p>OIG's portfolio on drug pricing and reimbursement focuses on the following areas:</p>

<h3>Data Integrity</h3>
<p>OIG work reviewing the accuracy of the data used in determining Federal drug reimbursement and rebate amounts as well as CMS's oversight and management of that data.</p>  

<h3>Program Compliance</h3> 
<p>OIG work examining whether drug manufacturers, State Medicaid agencies, and other entities are complying with statutory and program requirements. </p> 

<h3>Reimbursement Policy</h3>
<p>OIG work examining the financial impact of drug reimbursement and rebate policies on Federal spending. </p>

<h3>Spending Trends</h3>
<p>OIG work describing how market prices impact Federal spending for prescription drugs. </p>

<h3>Incentive Alignment</h3>
<p>OIG work exploring situations in which entities involved with HHS programs may have incentives not aligned with HHS program goals, adversely affecting those programs and their beneficiaries.</p>  


</div> 
